OMCL · Omnicell, Inc.
$32.65
+1.26% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$1B
Trailing P/E
39.8
Forward P/E
15.4
Dividend yield
—
Beta
0.97
Avg volume
1M
Employees
3K
Daily Change %
1.26%
5 Days Change
-2.12%
10 Days Change
-4.32%
30 Days Change
-8.74%
60 Days Change
-25.11%
Month to Day Change
-2.52%
Year to Day Change
-25.74%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OMCL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-03
Latest call per bank · past 12 months
Wells Fargo
Overweight$50.00
+55.0% vs priceBank of America
Neutral$46.00
+42.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Piper Sandler | Reiterates | Overweight | $55.00 → $45.00 |
| 2026-07-31 | Wells Fargo | Maintains | Overweight | $55.00 → $50.00 |
| 2026-07-31 | Keybanc | Maintains | Overweight | $70.00 → $65.00 |
| 2026-04-29 | Keybanc | Maintains | Overweight | $60.00 → $70.00 |
| 2026-04-23 | Wells Fargo | Maintains | Overweight | $52.00 → $55.00 |
| 2026-02-06 | Piper Sandler | Reiterates | Overweight | $63.00 → $49.00 |
| 2026-02-02 | Benchmark | Maintains | Buy | $50.00 → $60.00 |
| 2026-01-08 | Keybanc | Upgrade | Sector Weight → Overweight | $0.00 → $60.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 15.5% below the 50-day MA ($38.65).
- Price vs 200-day MA: Trading 19.7% below the 200-day MA ($40.67).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.03) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($29.46) and high ($51.39).
OMCL Price Chart
Loading chart for OMCL…
Fundamentals
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
More in Health Information Services
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.